1261776-69-5 Usage
Uses
Used in Pharmaceutical Industry:
(2-bromo-5-methylphenyl)methanamine is used as an intermediate in the synthesis of various pharmaceuticals for its contribution to the development of biologically active molecules.
Used in Organic Compounds Synthesis:
(2-bromo-5-methylphenyl)methanamine is used as a building block in the synthesis of organic compounds due to its chemical properties and reactivity.
Used in Agrochemical Production:
(2-bromo-5-methylphenyl)methanamine is used as an intermediate in the production of agrochemicals, contributing to the development of effective and targeted agricultural products.
Used in Specialty Chemicals Industry:
(2-bromo-5-methylphenyl)methanamine is used as a component in the production of specialty chemicals, where its unique properties are leveraged for specific applications.
Used in Advanced Materials Synthesis for Pharmaceutical Industry:
(2-bromo-5-methylphenyl)methanamine is used as a building block in the synthesis of advanced materials for the pharmaceutical industry, potentially enhancing the properties and effectiveness of drug formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 1261776-69-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,1,7,7 and 6 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1261776-69:
(9*1)+(8*2)+(7*6)+(6*1)+(5*7)+(4*7)+(3*6)+(2*6)+(1*9)=175
175 % 10 = 5
So 1261776-69-5 is a valid CAS Registry Number.
1261776-69-5Relevant academic research and scientific papers
KRAS G12C INHIBITORS
-
Paragraph 0805, (2020/07/25)
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
NEW CRTH2 ANTAGONISTS
-
Page/Page column 154, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
